Catalyst
Slingshot members are tracking this event:
Gilead Sciences (GILD) plan to fully enroll Phase 3 STELLAR trial for nonalcoholic steatohepatitis (NASH) evaluating selonsertib in treating F3 fibrosis by first half of 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 13, 2018
Occurred Source:
http://www.gilead.com/news/press-releases/2018/4/gilead-presents-data-on-multiple-investigational-regimens-for-the-treatment-of-patients-with-nonalcoholic-steatohepatitis-nash-and-advanced-fibrosis-at-the-international-liver-congress-2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nash Fibrosis, Selonsertib, Phase 3, Stellar
